Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hayley C Whitaker

Showing results (1-10 of 67) with videos related to

Pageof 7
Sort By:
Current Cancer Drug Targets|August 20, 2010
RAS pathways in prostate cancer - mediators of hormone resistance?Hayley C Whitaker, David E Neal
Communications Biology|May 13, 2021
The oncological relevance of fragile sites in cancerBenjamin S Simpson, Hayley Pye, Hayley C Whitaker
Journal of Cell Science|March 6, 2008
Structural basis for the nuclear import of the human androgen receptorMark L Cutress, Hayley C Whitaker, Ian G Mills, et al.
The Prostate|October 1, 2009
The potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic targetHayley C Whitaker, Anne Y Warren, Rosalind Eeles, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|September 13, 2020
Conspicuity of prostate cancer on multiparametric magnetic resonance imaging: A cross-disciplinary translational hypothesisJoseph M Norris, Benjamin S Simpson, Alex Freeman, et al.
Journal of Biophotonics|November 20, 2021
Effects of photobiomodulation therapy on regulation of myogenic regulatory factor mRNA expression in vivo: A systematic reviewDavid W Shepherd, Joseph M Norris, Benjamin S Simpson, et al.
The Prostate|May 7, 2008
Alterations in beta-catenin expression and localization in prostate cancerHayley C Whitaker, Joanne Girling, Anne Y Warren, et al.
Molecular Oncology|February 18, 2014
Regulation of the localisation and function of the oncogene LYRIC/AEG-1 by ubiquitination at K486 and K491Hayley J Luxton, Karin Barnouin, Gavin Kelly, et al.
Signal Transduction and Targeted Therapy|April 17, 2020
PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancerSabina Luszczak, Christopher Kumar, Vignesh Krishna Sathyadevan, et al.
The Prostate|April 19, 2007
Labeling and identification of LNCaP cell surface proteins: a pilot studyHayley C Whitaker, David P B Stanbury, Claire Brinham, et al.
Pageof 7

Showing results (1-10 of 67) with videos related to

Sort By:
Pageof 7
Current Cancer Drug Targets|August 20, 2010
RAS pathways in prostate cancer - mediators of hormone resistance?Hayley C Whitaker, David E Neal
Communications Biology|May 13, 2021
The oncological relevance of fragile sites in cancerBenjamin S Simpson, Hayley Pye, Hayley C Whitaker
Journal of Cell Science|March 6, 2008
Structural basis for the nuclear import of the human androgen receptorMark L Cutress, Hayley C Whitaker, Ian G Mills, et al.
The Prostate|October 1, 2009
The potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic targetHayley C Whitaker, Anne Y Warren, Rosalind Eeles, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|September 13, 2020
Conspicuity of prostate cancer on multiparametric magnetic resonance imaging: A cross-disciplinary translational hypothesisJoseph M Norris, Benjamin S Simpson, Alex Freeman, et al.
Journal of Biophotonics|November 20, 2021
Effects of photobiomodulation therapy on regulation of myogenic regulatory factor mRNA expression in vivo: A systematic reviewDavid W Shepherd, Joseph M Norris, Benjamin S Simpson, et al.
The Prostate|May 7, 2008
Alterations in beta-catenin expression and localization in prostate cancerHayley C Whitaker, Joanne Girling, Anne Y Warren, et al.
Molecular Oncology|February 18, 2014
Regulation of the localisation and function of the oncogene LYRIC/AEG-1 by ubiquitination at K486 and K491Hayley J Luxton, Karin Barnouin, Gavin Kelly, et al.
Signal Transduction and Targeted Therapy|April 17, 2020
PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancerSabina Luszczak, Christopher Kumar, Vignesh Krishna Sathyadevan, et al.
The Prostate|April 19, 2007
Labeling and identification of LNCaP cell surface proteins: a pilot studyHayley C Whitaker, David P B Stanbury, Claire Brinham, et al.
Pageof 7